Comment from Biotechnology Innovation Organization (BIO)

Summary: The Biotechnology Innovation Organization (BIO) supports the draft guidance on Master Protocols for Drug and Biological Product Development, noting that it comprehensively summarizes common practices. However, the organization provides numerous specific recommendations to improve the guidance, including clarifying definitions, expanding the scope to include basket trials and pediatrics, and providing more detail on adaptive designs and sample size considerations.